Chris Degnan - 31 Jan 2026 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Reporting relationship
Chief Financial Officer
Issuer ticker
URGN
Reported as of
31 Jan 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
03 Feb 2026, 17:16:53 UTC
Prior SEC filing
09 Oct 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jason D. Smith, Attorney-in-Fact

Key filing fact

Chris Degnan filed Form 4 for UroGen Pharma Ltd. (URGN) on 03 Feb 2026.

Key facts

  • This page summarizes Chris Degnan's Form 4 filing for UroGen Pharma Ltd. (URGN).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 03 Feb 2026, 17:16.

Change

  • Previous filing in this sequence was filed on 09 Oct 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001741968 Primary reporting owner

Degnan Chris

Relationship
Chief Financial Officer
Address
400 ALEXANDER PARK DRIVE, PRINCETON
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Signature date
03 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

URGN transaction Derivative

Restricted Stock Units

Award

Transaction value
$0
Shares
+32,609
Change %
Price
$0.000000
Shares after
32,609
Date
31 Jan 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
32,609
Exercise price
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

Footnote F2

1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .